S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

SGMO Sangamo Therapeutics Inc

2.37

-0.10 (-4.05%)

After Hours

Last Updated: 15:16:15

Delayed by 15 minutes

Form EFFECT - Notice of Effectiveness

Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From Nov 2024 to Dec 2024

Click Here for more Sangamo Therapeutics Charts.

Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From Dec 2023 to Dec 2024

Click Here for more Sangamo Therapeutics Charts.

Sangamo Therapeutics Inc News

Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
Thursday 19 December 2024 (5 days ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 26 November 2024 (4 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 26 November 2024 (4 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 26 November 2024 (4 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 26 November 2024 (4 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 26 November 2024 (4 weeks ago) • Edgar (US Regulatory)

Form EFFECT - Notice of Effectiveness
Tuesday 19 November 2024 (1 month ago) • Edgar (US Regulatory)

Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
Tuesday 19 November 2024 (1 month ago) • Business Wire

Form S-8 - Securities to be offered to employees in employee benefit plans
Tuesday 12 November 2024 (1 month ago) • Edgar (US Regulatory)

Form S-3 - Registration statement under Securities Act of 1933
Tuesday 12 November 2024 (1 month ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Tuesday 12 November 2024 (1 month ago) • Edgar (US Regulatory)

Form 8-K - Current report
Tuesday 12 November 2024 (1 month ago) • Edgar (US Regulatory)

More Sangamo Therapeutics Inc News Articles

Hallmark Venture (PK)

Anavex Life Sciences

Asia Broadband (PK)

Intergrated Cannabis Sol... (PK)

SMC Entertainment (PK)

Digital Brand Media and ... (PK)

Bioelectronics (PK)

AMC Entertainment

Code Green Apparel (PK)

Kraig Biocraft Laborator... (QB)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions